Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 12;34(5):627-632.
doi: 10.1515/jpem-2020-0457. Print 2021 May 26.

Screening for asymptomatic diabetes and metabolic comorbidities in pediatric patients during therapy for acute lymphoblastic leukemia

Valerie Larouche  1 , Caroline Bellavance  2 , Pauline Tibout  3 , Sebastien Bergeron  3 , David Simonyan  4 , Julie Gagné  3
Affiliations

Screening for asymptomatic diabetes and metabolic comorbidities in pediatric patients during therapy for acute lymphoblastic leukemia

Valerie Larouche et al. J Pediatr Endocrinol Metab. .

Abstract

Objectives: Chronic metabolic disturbances related to cancer treatment are well reported among survivors of pediatric acute lymphoblastic leukemia (ALL). However, few studies have investigated the incidence of these complications during the phase of chemotherapy. We evaluated the incidence of acute metabolic complications occurring during therapy in our cohort of patients diagnosed with ALL.

Methods: A prospective study involving 50 ALL pediatric patients diagnosed and treated between 2012 and 2016 in our oncology unit. We collected weight, blood pressure, fasting plasma glucose and hemoglobin A1C (HBA1c) levels during the two years of therapy.

Results: Obesity and overweight occurred in 43 and 25%, respectively among patients and have been reached at 12 months of chemotherapy. About 26% of the patients developed high blood pressure and 14% experienced hyperglycemias without meeting diabetes criteria. There was a significant decrease of HBA1c levels between the beginning and the end of therapy (p<0.0001).

Conclusions: Increase of body mass index in our ALL pediatric patients occurred during the first months of therapy and plateaued after a year of treatment. We should target this population for early obesity prevention. HbA1c levels measured during therapy did not reveal diabetes criteria. Hence, fasting blood glucose levels are sufficient to monitor ALL pediatric patients' glycemia.

Keywords: chemotherapy; children; hyperglycemia; leukemia; metabolic complications.

PubMed Disclaimer

References

    1. Ward, E, DeSantis, C, Robbins, A, Kohler, B, Jemal, A. Childhood and adolescent cancer statistics. CA A Cancer J Clin 2014;64:83–103. https://doi.org/10.3322/caac.21219.
    1. Noone, AM, Howlader, N, Krapcho, M, Miller, D, Brest, A, Yu, M, et al.. SEER cancer statistics review. Bethesda, MD: National Cancer Institute; 1975–2015. Available from: https://seer.cancer.gov/csr/1975_2015/ [Based on November 2017 SEER data submission, posted to the SEER web site, April 2018].
    1. Place, AE, Stevenson, KE, Vrooman, LM, Harris, HM, Hunt, SK, O’Brien, JE, et al.. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol 2015;16:1677–90. https://doi.org/10.1016/s1470-2045(15)00363-0.
    1. Koltin, D, Sung, L, Naqvi, A, Urbach, SL. Medication-induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics. Support Care Canc 2012;20:2009–15. https://doi.org/10.1007/s00520-011-1307-5.
    1. Pui, CH, Burghen, GA, Bowman, WP, Aur, RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 1981;99:46–50. https://doi.org/10.1016/s0022-3476(81)80955-9.

MeSH terms

LinkOut - more resources